Orthogonal Light- and Enzyme-Triggered and-Gate Prodrugs for Senolytic Therapy.
Key claim: A sequential light- and SA-β-gal enzyme AND-gate prodrug strategy preferentially activates senolytic payloads (doxorubicin and an ARV-771 PROTAC) in senescent cells and organoids after 390 nm irradiation, improving senolytic index versus parent compounds under tested in vitro/ex vivo conditions.
Abstract
Senescence-associated β-galactosidase (SA-β-gal) is widely used to target senescent cells, but its activity in non-senescent tissues can limit selectivity. Here, we developed a light-enzyme AND-gate strategy in which an o-nitrobenzyl photocage blocks β-galactoside cleavage until 390 nm irradiation. The strategy was evaluated using a fluorescent probe (LS-C), a doxorubicin prodrug (LS-D), and an ARV-771-based PROTAC (LS-A). LS-C exhibited dual-trigger-dependent fluorescence activation, while LS-D preferentially induced apoptosis and LS-A promoted BRD4 degradation in senescent cells following light activation. Across multiple senescence models, LS-D and LS-A showed higher senolytic indices than their corresponding parent compounds. In senescent lung cancer patient-derived organoids, LS-D combined with light increased organoid death, whereas either treatment alone had minimal effects. These results provide proof-of-concept evidence for sequential light-enzyme AND-gating as a strategy for controlling payload activation in senescent cells under the tested in vitro and ex vivo conditions.
Why this matters
Off-target toxicity of broad-acting senolytics like navitoclax and PROTAC-based degraders is a key bottleneck between promising preclinical biology and human use. Requiring two independent triggers — exogenous 390 nm light AND the senescence-enriched SA-β-gal enzyme — to activate the payload is a design strategy aimed at sharpening senescent-cell selectivity beyond what single-trigger prodrugs or free compounds achieve. The result is a preclinical delivery proof-of-concept in cells and organoids, not evidence that selectivity holds in a whole organism or that it translates to clinical benefit.